GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
M

Medicure MPH.V · CAD

Health Care · TSX Venture · 🇨🇦 Canada

Compare

3.78

+0.80%

Close of 9 Nov 2026, in CAD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Medicure

Its shares trade on TSX Venture under the ticker MPH.V. It has been listed since 30 March 1999. In the fiscal year to 31 December 2025, it reported revenue of C$28.9m and a net loss of C$7.1m. At that date it held total assets of C$24.9m and shareholders' equity of C$12.9m.

Medicure, Inc. is a pharmaceutical company, which engages in the research, clinical development, and commercialization of cardiovascular therapeutics. The company is headquartered in Winnipeg, Manitoba. The firm operates in the biopharmaceutical industry segment. The firm's primary operating focus is on the sale and marketing of its acute care cardiovascular drug, AGGRASTAT (tirofiban hydrochloride) owned by its subsidiary, Medicure International, Inc. and distributed in the United States and its territories through the Company's United States subsidiary, Medicure Pharma, Inc. AGGRASTAT, a glycoprotein IIb/IIIa inhibitor (GPI), is used for the treatment of acute coronary syndrome (ACS). The firm is also engaged in the development of TARDOXAL for neurological disorders, such as Tardive Dyskinesia (TD). The firm has completed Phase IIa stage of development for TARDOXAL. The firm is also developing Transdermal AGGRASTAT, a cure for acute cardiology. Transdermal AGGRASTAT is in preclinical-stage of development.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
30 Mar 1999
Employees
50

Leadership

Pay as last reported

  • Dr. Albert FriesenChairman of the Board, Chief Executive OfficerC$216,000
  • Dr. Neil OwensPresident, Chief Operating OfficerC$205,000
  • Mr. Haaris UddinChief Financial OfficerC$128,195
  • Mr. James KinleyDirector, since 2011C$10,000
  • Mr. Brent FawkesIndependent DirectorC$15,000
  • Dr. Arnold NaimarkIndependent DirectorC$15,000
  • Mr. Peter QuickIndependent DirectorC$10,000

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Medicure Inc possesses several key strengths that contribute to its success in the pharmaceutical industry:

Weaknesses

  • Despite its strengths, Medicure Inc also has some areas that need improvement:

Opportunities

  • Medicure Inc can leverage various opportunities to grow and expand its market share:

Threats

  • Medicure Inc should be mindful of potential threats that may impact its performance:

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.